Fortress Biotech’s Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million
Rhea-AI Summary
Fortress Biotech (Nasdaq: FBIO) and majority-owned subsidiary Cyprium Therapeutics closed the sale of Cyprium’s Rare Pediatric Disease Priority Review Voucher for gross proceeds of $205 million on March 30, 2026. Fortress expects to receive over $100 million of the proceeds, improving liquidity for business development.
The PRV was issued after FDA approval of ZYCUBO on January 12, 2026. Cyprium remains eligible for tiered royalties on ZYCUBO sales and up to approximately $128 million in aggregate sales milestones from Sentynl. Cyprium must pay 20% of PRV proceeds to the Eunice Kennedy Shriver National Institute of Child Health and Human Development.
Positive
- PRV sale generated gross proceeds of $205 million
- Fortress expects to receive over $100 million from the transaction
- Cyprium eligible for up to ~$128 million in aggregate sales milestones
- PRV issued following FDA approval of ZYCUBO on Jan 12, 2026
Negative
- Cyprium obligated to pay 20% of PRV proceeds to NIH (reduces net proceeds by ~20%)
News Market Reaction – FBIOP
In the Mar 31 session, FBIOP gained 4.82%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 23 | PRV sale agreement | Positive | +23.0% | Definitive agreement to sell PRV for $205M with milestone potential. |
| Jan 13 | FDA approval | Positive | +23.5% | FDA approval of ZYCUBO and issuance of PRV plus milestone rights. |
| Dec 15 | Regulatory update | Positive | +23.3% | FDA acceptance of CUTX-101 NDA resubmission with new PDUFA date. |
| Nov 14 | Earnings report | Positive | +7.2% | Q3 2025 revenue growth and return to net income with cash build. |
| Oct 21 | Clinical trial start | Positive | -0.9% | First patients dosed in two global Phase 3 dotinurad trials. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent Fortress/Cyprium regulatory and transaction news often coincided with double-digit positive moves, except one clinical milestone that saw a small decline.
Over the past six months, Fortress reported multiple positive catalysts, including FDA acceptance of the CUTX-101 NDA (Dec 15, 2025), ZYCUBO FDA approval (Jan 13, 2026), and the initial agreement to sell the PRV for $205M (Feb 23, 2026). These events saw strong positive reactions of ~23% in several cases. Earlier, Q3 2025 earnings on Nov 14, 2025 and a Phase 3 trial start on Oct 21, 2025 also contributed to the trajectory. Today’s closing of the PRV sale directly follows through on that February agreement.
Key Terms
rare pediatric disease priority review voucher regulatory
priority review voucher regulatory
tiered royalties financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
MIAMI, March 30, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc. (“Cyprium”), today announced the closing of the sale of Cyprium’s Rare Pediatric Disease Priority Review Voucher (“PRV”) for gross proceeds of
“The sale of the PRV by Cyprium is a transformational corporate transaction for both Cyprium and Fortress. As the majority shareholder of Cyprium, Fortress expects to receive over
In December 2023, Sentynl Therapeutics, Inc. (“Sentynl”) assumed full responsibility for the development and commercialization of ZYCUBO® (copper histidinate, formerly known as CUTX-101) from Cyprium. The PRV was issued upon approval of ZYCUBO® by the U.S. Food and Drug Administration (“FDA”) on January 12, 2026. Pursuant to the transaction with Sentynl, the PRV was immediately transferred to Cyprium and has now been sold by Cyprium.
Cyprium remains eligible to receive tiered royalties on net sales of ZYCUBO® and up to approximately
About Cyprium Therapeutics
Cyprium Therapeutics, Inc. (“Cyprium”) is focused on the development of novel therapies for the treatment of Menkes disease and related copper metabolism disorders. In March 2017, Cyprium entered into a Cooperative Research and Development Agreement with the Eunice Kennedy Shriver National Institute of Child Health and Human Development (“NICHD”), part of the NIH, to advance the clinical development of CUTX-101 (Copper Histidinate injection) for the treatment of Menkes disease. In 2023, Cyprium completed the transfer of its proprietary rights and assigned its FDA documents pertaining to CUTX-101 to Sentynl Therapeutics, Inc. ZYCUBO® (formerly CUTX-101) was U.S. FDA-approved in 2026 for the treatment of Menkes disease in pediatric patients. Cyprium and NICHD also have an ongoing worldwide, exclusive license agreement to develop and commercialize adeno-associated virus (AAV)-based gene therapy, called AAV-ATP7A, to deliver working copies of the copper transporter that is defective in patients with Menkes disease, and to be used in combination with CUTX-101; AAV-ATP7A gene therapy is currently in pre-clinical development and has received FDA Orphan Drug Designation. Cyprium was founded by, and is a majority-owned subsidiary of, Fortress Biotech, Inc. (Nasdaq: FBIO). For more information, visit www.cypriumtx.com.
About Fortress Biotech
Fortress Biotech, Inc. (“Fortress”) is an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty income. The company has multiple marketed prescription pharmaceutical products and programs in development at Fortress, at its majority-owned and majority-controlled partners and subsidiaries and at partners and subsidiaries it founded and in which it holds significant minority ownership positions. Fortress’ portfolio is being commercialized and developed for various therapeutic areas including oncology, dermatology, and rare diseases. Fortress’ model is focused on leveraging its significant biopharmaceutical industry expertise and network to further expand and advance the company’s portfolio of product opportunities. Fortress has established partnerships with some of the world’s leading academic research institutions and biopharmaceutical companies to maximize each opportunity to its full potential, including AstraZeneca, City of Hope, Nationwide Children’s Hospital, Columbia University, Dana-Farber Cancer Center and Sentynl Therapeutics. For more information, visit www.fortressbiotech.com.
Forward-Looking Statements
Statements in this press release that are not descriptions of historical facts are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. The words “anticipates,” “believes,” “can,” “continue,” “could,” “estimates,” “expects,” “intends,” “may,” “might,” “plans,” “potential,” “predicts,” “should,” or “will” or the negative of these terms or other comparable terminology are generally intended to identify forward-looking statements. These forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated include risks relating to: our growth strategy, financing and strategic agreements and relationships; our need for substantial additional funds and uncertainties relating to financings; uncertainty related to the timing and amounts expected to be realized from future milestone, contingent value right, royalty or similar future revenue streams, if at all; our ability to identify, acquire, close and integrate product candidates successfully and on a timely basis; our ability to attract, integrate and retain key personnel; the early stage of products under development; the results of research and development activities; uncertainties relating to preclinical and clinical testing; our ability to obtain regulatory approval for products under development; our ability to successfully commercialize products for which we receive regulatory approval; our ability to secure and maintain third-party manufacturing, marketing and distribution of our and our partner companies’ products and product candidates; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as may be required by law, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The information contained herein is intended to be reviewed in its totality, and any stipulations, conditions or provisos that apply to a given piece of information in one part of this press release should be read as applying mutatis mutandis to every other instance of such information appearing herein.
Company Contact:
Jaclyn Jaffe
Fortress Biotech, Inc.
(781) 652-4500
ir@fortressbiotech.com
Media Relations Contact:
Tony Plohoros
6 Degrees
(908) 591-2839
tplohoros@6degreespr.com
